---
document_datetime: 2025-08-27 17:51:29
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nilotinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nilotinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2001963
conversion_datetime: 2025-12-22 00:41:36.878345
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nilotinib Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | This was an application for a group of | 26/08/2025                          |                                             | Annex II and                     |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291910                        | variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted   |            |     | PL          |                                                                                                                                                                                                                                                                                                                  |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000282587    | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Change in the holding time of an intermediate - Accepted                                                                                                                                        | 01/08/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                  |
| Variation type IA_IN / EMA/VR/0000280383 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                               | 20/06/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                  |
| Variation type IB / EMA/VR/0000253330    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted To update the sections 4.2, 4.4, 5.2 of the SmPC and section 3 of the PL to carve in the information for administration of nilotinib                                                                                                                                          | 07/04/2025 |     | SmPC and PL | To update the sections 4.2, 4.4, 5.2 of the SmPC and section 3 of the PL to carve in the information for administration of nilotinib with apple sauce in patients with swallowing problems in line with the information of reference product. In addition the MAH took this opportunity to correct the number of |

<div style=\"page-break-after: always\"></div>

|                                       | with apple sauce in patients with swallowing problems in line with the information of reference product. In addition the MAH took this opportunity to correct the number of units per blister.                                                                                                                                                                                                                                                                              |            |     | units per blister.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| Variation type IB / EMA/VR/0000256134 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minor change to the restricted part of an Active Substance Master File - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted | 01/04/2025 | N/A |                      |
| Variation type IA / EMA/VR/0000261776 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                                                                                | 31/03/2025 | N/A |                      |
| Variation type IA / EMA/VR/0000261828 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                                                                                | 31/03/2025 | N/A |                      |